FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
BioSpace8d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
WebMD3d
What to Know About the New Nasal Spray for Tough Depression
The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...
Health and Me on MSN7d
FDA Approves ‘Spravato’ Nasal Spray As A Standalone Depression Treatment
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
BioSpace7d
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Popular Science8d
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...
NBC Washington9d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
Mattingly said patients can now choose to take Spravato with or without an oral antidepressant, especially if those pills aren't improving their symptoms and are causing undesirable side effects ...